Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.